Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20.

Albendazole, an FDA approved drug, carries strong therapeutic potential to treat colon cancers which are aggressive and potentially resistant to conventional chemotherapeutic agents. Our findings also lay the groundwork for further clinical testing.